Clinical Trials Logo
  1. Home
  2. Disease-Free Survival
  3. NCT01236989

Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC — ARversusNAR  

Overall Survival Clinical Trial

Official title:
Anatomical Liver Resection by Means of Ultrasound-guided Vessel Compression Versus Non-anatomical Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial

Clinical Trial Summary

Prognostic impact of AR vs NAR

Clinical Trial Description

Whether anatomical is better than non anatomical resection for HCC is still debated. This prospective randomized study aimed to address which approach is better in terms of patients prognosis. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01236989
Study type Interventional
Source University of Milan
Contact Guido Torzilli, MD, PhD
Phone +39 02 8224
Email guido.torzilli@unimi.it
Status Not yet recruiting
Phase N/A
Start date January 2011
Completion date December 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04025840 - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Phase 4
Completed NCT04111926 - Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery Phase 4
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Recruiting NCT03910140 - TILA-TACE in Treatment of Hepatocellular Carcinoma N/A
Completed NCT03923400 - Jejunoileal vs Gastric GIST in the Era of Imatinib.
Withdrawn NCT02201381 - Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Phase 3
Recruiting NCT05392257 - Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial Phase 2
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting NCT05310357 - Chromosomal Instability in Ovarian Cancer
Active, not recruiting NCT04245644 - Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
Recruiting NCT04245410 - Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
Completed NCT02980185 - Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer N/A
Recruiting NCT03967457 - Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Recruiting NCT04050787 - Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Completed NCT03726021 - Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT02942238 - Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC) N/A
Recruiting NCT05218629 - Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer Phase 2